Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs

被引:0
|
作者
Huo, Hong [1 ,2 ]
Wang, Jinming [1 ]
Li, Chan [3 ]
Xiao, Shuang [1 ]
Wang, Han [1 ]
Ge, Jinying [1 ]
Zhong, Gongxun [1 ,2 ]
Wen, Zhiyuan [1 ,2 ]
Wang, Chong [1 ,2 ]
Lang, Qiaoling [3 ]
Chen, Lili [3 ]
Wang, Zilong [3 ]
Wang, Jinliang [1 ,2 ]
Wang, Xijun [1 ]
He, Xijun [2 ]
Guan, Yuntao [2 ]
Shuai, Lei [1 ,2 ]
Bu, Zhigao [1 ,2 ,4 ]
机构
[1] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Anim Dis Control & Prevent, Harbin, Peoples R China
[2] Chinese Acad Agr Sci, Harbin Vet Res Inst, Natl High Containment Lab Anim Dis Control & Preve, Harbin, Peoples R China
[3] CSPC Pharmaceut Grp Co Ltd, CSPC Zhongqi Pharmaceut Technol Shijiazhuang Co Lt, Shijiazhuang, Hebei, Peoples R China
[4] Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2024年 / 14卷
基金
黑龙江省自然科学基金;
关键词
SARS-CoV-2; mRNA vaccine; safety; neutralizing antibody; susceptible animals; TRANSMISSION;
D O I
10.3389/fcimb.2024.1468775
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Minks, cats, and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have a high risk of transmitting SARS-CoV-2 to humans. The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has been proven to be an efficient coronavirus disease 2019 (COVID-19) vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta, and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue foxes, and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A novel mRNA vaccine, SYS6006, against SARS-CoV-2
    Xu, Ke
    Lei, Wenwen
    Kang, Bin
    Yang, Hanyu
    Wang, Yajuan
    Lu, Yanli
    Lv, Lu
    Sun, Yufei
    Zhang, Jing
    Wang, Xiaolin
    Yang, Mengjie
    Dan, Mo
    Wu, Guizhen
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [2] Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial
    Jin, Fei
    Qiu, Yuanzheng
    Wu, Zhiwei
    Wang, Yuan-Hui
    Cai, Chengye
    Fu, Liangcai
    Jiao, Wenbin
    Wang, Huixian
    Gao, Ming
    Su, Chang
    Ma, Jun-Heng
    Xu, Yan
    Huang, Chao-Chao
    Zhang, Qing
    Ni, Shaonan
    Zhao, Maosheng
    Guo, Lixian
    Ji, Li
    Yang, Hanyu
    Zhao, Yuliang
    Li, Chunlei
    Lu, Xiang
    Su, Yu-Wen
    Li, Qi
    VACCINE, 2024, 42 (07) : 1561 - 1570
  • [3] Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine
    Huang, Jianying
    Qiu, Yuanzheng
    Luo, Lin
    Wu, Jianyuan
    Hu, Di
    Zhong, Xiang
    Lin, Jiawei
    Guo, Lixian
    Yang, Hanyu
    Li, Chunlei
    Wang, Xinghuan
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (03)
  • [4] The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial
    Zhou, Chunhua
    Qiu, Yuanzheng
    Wang, Jianxin
    Zhong, Xiang
    Zhu, Xiufang
    Huang, Xiaojing
    Yang, Lan
    Ji, Qiaolei
    Zhou, Feifei
    Wu, Shunquan
    Yang, Mengjie
    Zhang, Jing
    Liu, Kaili
    Ji, Li
    Yang, Hanyu
    Li, Chunlei
    Zhao, Yuanyuan
    EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
  • [5] Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
    Chen, Gui-Ling
    Qiu, Yuan-Zheng
    Wu, Kai-Qi
    Wu, Ying
    Wang, Yuan-Hui
    Zou, Yu-Ying
    Peng, Cong-Gao
    Zhao, Jie
    Su, Chang
    Ma, Jun-Heng
    Ni, Shao-Nan
    Wang, Xing
    Jin, Ting-Han
    Jiang, Qi
    Guo, Tong
    Xu, Yan
    Huang, Chao-Chao
    Zhang, Qing
    Liu, Kai-Li
    Ji, Li
    Yang, Han-Yu
    Li, Chun-Lei
    Su, Yu-Wen
    Lu, Xiang
    Li, Lan-Juan
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [6] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Anderson, E. J.
    Rouphael, N. G.
    Widge, A. T.
    Jackson, L. A.
    Roberts, P. C.
    Makhene, M.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A. B.
    Flach, B.
    Lin, B. C.
    Doria-Rose, N. A.
    O'Dell, S.
    Schmidt, S. D.
    Corbett, K. S.
    Swanson, P. A., II
    Padilla, M.
    Neuzil, K. M.
    Bennett, H.
    Leav, B.
    Makowski, M.
    Albert, J.
    Cross, K.
    Edara, V. V.
    Floyd, K.
    Suthar, M. S.
    Martinez, D. R.
    Baric, R.
    Buchanan, W.
    Luke, C. J.
    Phadke, V. K.
    Rostad, C. A.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25): : 2427 - 2438
  • [7] mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
    Jin, Yingqi
    Hou, Chen
    Li, Yonghao
    Zheng, Kang
    Wang, Chuan
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [8] The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
    Zitt, Emanuel
    Davidovic, Tamara
    Schimpf, Judith
    Abbassi-Nik, Armin
    Mutschlechner, Beatrix
    Ulmer, Hanno
    Benda, Magdalena A.
    Sprenger-Maehr, Hannelore
    Winder, Thomas
    Lhotta, Karl
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
    Chu, Laurence
    McPhee, Roderick
    Huang, Wenmei
    Bennett, Hamilton
    Pajon, Rolando
    Nestorova, Biliana
    Leav, Brett
    VACCINE, 2021, 39 (20) : 2791 - 2799
  • [10] CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
    Jin, Lairun
    Li, Zhuopei
    Zhang, Xiaoyin
    Li, Jingxin
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)